Resultados de investigación

El aislamiento de base es una técnica de protección sismorresistente para edificaciones, con amplio y exitoso uso a nivel mundial. En Colombia actualmente existen algunos edificios que incorporan esta técnica, los cuales fueron diseñados bajo los requisitos de la normativa americana vigentes en la época, como ASCE 7-10. Dicho documento ha sido recientemente actualizado a su versión 2016, con importantes cambios técnicos respecto a su predecesor. ASCE 7-16 incorpora resultados de las investigaciones más recientes en cuanto a aislamiento sísmico se refiere; en consecuencia, las futuras edificaciones que empleen esta técnica y que sean diseñadas y construidas en el país deberían seguir dicha regulación. Por todo lo anterior, en el presente trabajo se evidencia la necesidad de hacer un análisis de esta nueva estrategia de diseño (para edificaciones con aislamiento de base) y discutir su aplicabilidad en el país., Base isolation is a successful and worldwide used seismic protection technique for buildings. In Colombia there are some buildings that incorporate this technology; were designed by following the current American regulations, namely ASCE 7-10. This document has been recently updated to its 2016 version, with important changes. ASCE 7-16 incorporates the results of the most recent research; thus, apparently, future isolated buildings should follow this document. These considerations highlight the necessity of analyzing the prescriptions of ASCE 7-16 (regarding base isolation of buildings) and discussing its applicability to Colombia., Peer Reviewed, Postprint (published version)

En este primer episodio, Santiago de Pablo y Virginia López de Maturana hablan sobre símbolos vascos. Descubriremos cuáles son los más importantes, su historia y la importancia que tienen para nuestra cultura. Además, conoceremos el origen del lauburu con Isabel Mellén y los fondos que atesora la Fundación Sancho el Sabio sobre el rock radical vasco con Ander Gondra. Gracias a Jabi Soto nos adentraremos en el fascinante mundo de los orígenes de la fotografía. ¡Descubre estos temas y mucho más en este primer episodio de El Podcast de Sancho el Sabio!

Cómo citar: Oliveira, Andrea; Zeler, Ileana & Ruiz-Mora,Isabel (Coord.). (2025, junio 02). Relaciones Públicas y Desinformación (No3) [Episodio de Audio Podcast.] En Relaciones Públicas al Descubierto., Descubre, con María-Isabel Míguez-González (Profesora Titular en el departamento de Comunicación Audiovisual y Publicidad en la Universidade de Vigo y grupo de investigación en comunicación para el servicio público (SEPCOM), María Laura García (Presidenta del Comité Empresarial del World Innovation and Change Management Institute ) y Leticia Rodríguez Fernández (Profesora Titular en el Departamento de Marketing y Comunicación y directora general de Comunicación Estratégica en la Universidad de Cádiz), cómo las Relaciones Públicas pueden ayudar a la sociedad a afrontar el reto de la desinformación con una visión crítica y prospectiva, Asociación de Investigadores en Relaciones Públicas (AIRP)

AGUDIZACIÓN DE LA EPOC (AEPOC), La Agudización de la Enfermedad Pulmonar Obstructiva Crónica (AEPOC) se define según la GesEPOC 2021 como un “episodio de inestabilidad clínica en un paciente EPOC como consecuencia del agravamiento de la limitación espiratoria al flujo aéreo o del proceso inflamatorio subyacente y se caracteriza por un empeoramiento agudo de los síntomas respiratorios respecto de la situación basal del individuo”., Yes

Anàlisis geoquímiques i fotos de visu i microscòpia de les mostres que integren la col·lecció de geostandards del Museu de Geologia Valentí Masachs (UPC Manresa). Análisis geoquímicas y fotos de visu y microscopio de las muestras que integran la colección de geostandares del Museo de Geología Valentí Masachs (UPC Manresa). Geochemical analyses and hand and microscopy pictures of the samples belonging to the geostandards collection of the Valenti Masachs Geology Museum (UPC Manresa). Analyses géochimiques et photographies au microscope et visu des échantillons qui forment la collection de geostandards du Musée de Géologie Valentí Masachs (UPC Manresa)., 1

Trial registration number NCT06540677, Introduction Although most cochlear implant (CI) users achieve good speech understanding in quiet without visual cues, they may have limited speech understanding in noise and often have poor music perception. The present study was designed to investigate the degree to which the use of Meludia training can improve music perception, music enjoyment and speech understanding in paediatric and postlingually deafened adult CI users. The study also aims to assess the participants’ changes in cognitive skills (attention and memory) and quality of life. Methods and analysis This randomised controlled trial will randomise new CI users and experienced CI users older than 6 years who meet the inclusion criteria in a 1:1 ratio to either a musical training (MT) group or a non-MT (NMT) group. The NMT group will receive standard care that does not include MT. Participants in the MT group will practise with Meludia software for 4 weeks and later for 12 additional weeks. Outcomes will include scores in: ‘Listening Up’ exercises, the -Music-Related Quality of Life questionnaire, the Music Questionnaire for Paediatric Population, Disyllables in silence, Matrix test, Mini Mental State Examination, Performance IQ and the Wechsler intelligence scale for children and the Assessment of Quality of Life—8 Dimensions questionnaire. The NMT group will receive standard care that does not include MT

Rationale Cognitive decline and dementia have been reportedly linked to atherosclerosis, the main cause of cardiovascular disease. Cohort studies identifying early brain alterations associated with subclinical atherosclerosis are warranted to understand the potential of prevention strategies before cerebral damage becomes symptomatic and irreversible. Methods & design The Progression of Early Subclinical Atherosclerosis (PESA) study is a longitudinal observational cohort study that recruited 4,184 asymptomatic middle-aged individuals (40-54 years) in 2010 in Madrid (Spain) to thoroughly characterize subclinical atherosclerosis development over time. In this framework, the PESA-Brain study has been designed to identify early structural, functional and vascular brain changes associated with midlife atherosclerosis and cardiovascular risk factors. The PESA-Brain study targets 1,000 participants at the 10-year follow-up PESA visit and consists of thorough neuropsychological testing, advanced multimodal neuroimaging, and quantification of blood-based neuropathological biomarkers. Primary hypothesis We hypothesize that, in middle-age, the presence of cardiovascular risk factors and a high burden of subclinical atherosclerosis will be associated with structural, functional and vascular brain alterations, greater amyloid burden and subtle cognitive impairment. We further hypothesize that the link between subclinical atherosclerosis and poor brain health in midlife will be mediated by cerebrovascular pathology and intracranial atherosclerosis. Enrollment dates The PESA-Brain study started in October 2020 and is estimated to be completed by December 2024. Conclusion This study is in a unique position to unveil novel relationships between cardiovascular and brain alterations in the health-to-disease transition, which may have important implications for interventional and therapeutic approaches., The PESA study is funded by CNIC and Santander Bank, Madrid, Spain and also receives funding from the European Regional Development Fund (ERDF–A Way to Build Europe), and the European Social Fund (ESF–Investing in Your Future). CNIC is a Severo Ochoa Center of Ex- cellence (CEX2020-001041-S) and is supported by the ISCIII, the Spanish Ministry for Science and Innovation and the Pro-CNIC Foundation

Background While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)–infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear. Methods This was a pilot multicenter randomized, placebo-controlled, double-blind study in which 78 HIV-infected, ART-naive subjects with <350 CD4 T cells/μL or AIDS were randomized to either daily PMT25341 (a mixture of synbiotics, omega-3/6 fatty acids and amino acids) or placebo for 48 weeks, each in combination with first-line ART. Primary endpoints were changes in CD4 T-cell counts and CD4/CD8 ratio from baseline to week 48 and safety. Secondary endpoints were changes in markers of T-cell activation, bacterial translocation, inflammation, and α and β microbiota diversity. Results Fifty-nine participants completed the follow-up with a mean CD4+ T-cell count of 221 ± 108 cells/μL and mean CD4/CD8 ratio of 0.26 ± 0.19. PMT25341 was well tolerated, without grade 3–4 adverse effects attributable to the intervention. While most of the assessed biomarkers improved during the follow-up in both arms, PMT25341-treated subjects did not experience any significant change, compared to placebo-treated subjects, in mean CD4+ T-cell count change (278 vs 250 cells/μL, P = .474) or CD4/CD8 ratio change (0.30 vs 0.32, P = .854). Similarly, we did not detect differences between treatment arms in secondary endpoints. Conclusions In HIV-infected patients initiating ART at advanced disease, the clear immunological benefits of ART were not enhanced by this nutritional intervention targeting the gut-associated lymphoid tissue and microbiota, This work was supported by the Instituto de Salud Carlos III (Plan Estatal de I+D+i 2013–2016, projects PI13/00438, AC15/00022, and PI15/00345, and the Spanish AIDS Research Network RD16/0025/0001project), the Spanish Ministry of Science and Competitiveness (project SAF2015-65878-R), and co-financed by the European Development Regional Fund “A Way to Achieve Europe.” The present investigation was also funded by the Instituto de Salud Carlos III and the Fundación Asociación Española contra el Cáncer within the ERA (European Research Area)-NET aligning national/regional translational cancer research programmes and activities (TRANSCAN)-2 program (grant number AC17/00022). S. S.-V. was supported by a grant from the Spanish Ministry of Science and Competitiveness (Contratos Juan Rodés, ECC/1051/2013)

Trial identifier: NCT04357808, Background: The use of IL-6 blockers in COVID-19 hospitalized patients has been associated with a reduction in mortality compared to standard care. However, many uncertainties remain pertaining to optimal intervention time, administration schedule, and predictors of response. To date, data on the use of subcutaneous sarilumab is limited and no randomized trial results are available. Methods: Open label randomized controlled trial at a single center in Spain. We included adult patients admitted with microbiology documented COVID-19 infection, imaging confirmed pneumonia, fever and/or laboratory evidence of inflammatory phenotype, and no need for invasive ventilation. Participants were randomly assigned to receive sarilumab, a single 400 mg dose in two 200 mg subcutaneous injections, added to standard care or standard care, in a 2:1 proportion. Primary endpoints included 30-day mortality, mean change in clinical status at day 7 scored in a 7-category ordinal scale ranging from death (category 1) to discharge (category 7), and duration of hospitalization. The primary efficacy analysis was conducted on the intention-to-treat population. Results: A total of 30 patients underwent randomization: 20 to sarilumab and 10 to standard care. Most patients were male (20/30, 67%) with a median (interquartile range) age of 61.5 years (56-72). At day 30, 2/20 (10%) patients died in the sarilumab arm vs. none (0/10) in standard care (Log HR 15.11, SE 22.64; p = 0.54). At day 7, no significant differences were observed in the median change in clinical status (2 [0-3]) vs. 3 [0-3], p = 0.32). Median time to discharge (days) was similar (7 [6-11] vs. 6 [4-12]; HR 0.65, SE 0.26; p = 0.27). No significant differences were detected in the rate of progression to invasive and noninvasive mechanical ventilation. Conclusions and relevance: Our pragmatic pilot study has failed to demonstrate the benefit of adding subcutaneous sarilumab to standard care for mortality by 30 days, functional status at day 7, or hospital stay. Findings herein do not exclude a potential effect of sarilumab in severe COVID-19 but adequately powered blinded randomized phase III trials are warranted to assess the impact of the subcutaneous route and a more selected target population

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations, Background COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. Methods/design The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to category 5, 6, or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. Trial registration ClinicalTrials.gov NCT04345523. Registered on 30 March, 2020. First posted date: April 14, 2020, This research is funded by the Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III, grant n° COV20/00072 (Royal Decree-Law 8/2020, of 17 March, on urgent extraordinary measures to deal with the economic and social impact of COVID-19), co-financed by the European Regional Development Fund (FEDER) “A way to make Europe,” and supported by SCReN (Spanish Clinical Research Network), ISCIII, project PT17/0017/0009. The funding institutions do not have any role in the design of the study, data collection, analysis, or interpretation of data, nor in writing the manuscript